Available Until 5/22/2027

Pharmacy Accreditation & Regulatory Compliance Certificate

Release DateMay 22, 2024
Expiration DateMay 22, 2027

ACPE Numbers: Various – see below
Activity Type: Application-based
CE Contact Hour(s): 22.5 contact hours
 

Overview

How can you identify an accreditation or regulatory compliance issue within your pharmacy before it becomes a problem? This certificate looks into this question as well as looking at the accreditation and regulatory compliance requirements themselves within a health-system pharmacy. To do this, the certificate covers the basics of creating a pharmacy compliance model, medication use systems and policy, supply chain compliance, risk evaluation and mitigation strategy (REMS), diversion monitoring and prevention, compounding compliance, and quality assurance, improvement, tools, and software.

Pharmacy Accreditation & Regulatory Compliance Certificate Requirements 

Once a learner has completed the educational curriculum, they will have the opportunity to complete an online comprehensive exam. Once the learner completes the exam (minimum 80% passing rate; unlimited attempts permitted), they will earn the professional certificate.

ACPE Provider with Commendation logo

   
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This professional certificate is intended for pharmacists and pharmacy technicians who have an interest in learning more about pharmacy accreditation standards as well as pharmacy regulations and compliance.

Learning Activity

ACPE Number

Contact Hours

Creating a Pharmacy Compliance Model: Accreditation and Compliance Basics

0204-0000-24-764-H04-P&T

3.0

Medication Use: Systems and Policy

0204-0000-24-765-H04-P&T

3.0

Supply Chain Compliance

0204-0000-24-766-H04-P&T

3.0

Risk Evaluation and Mitigations Strategy (REMS)

0204-0000-24-767-H04-P&T

2.75

Diversion Monitoring and Prevention

0204-0000-24-768-H04-P&T

3.5

Compounding Compliance

0204-0000-24-769-H04-P&T

4.5

Quality Improvement, Assurance, Tools, and Software

0204-0000-24-770-H04-P&T

2.75

  →  Final Assessment: (80% passing score required)

Creating a Pharmacy Compliance Model: Accreditation and Compliance Basics
ACPE: 0204-0000-24-764-H04-P&T
CE Hours: 3 contact hours
Activity Type: Application-based

  • Identify the federal agency that sets the requirements for hospitals.
  • List the accreditation organizations deemed by Medicare to survey hospitals.
  • State the pharmaceutical services Hospital Conditions of Participation.
  • Recall other sections of the Hospital Conditions of Participation that deal with medications.
  • Identify the scope of state board of pharmacy regulations.
  • Describe an approach to ensure continuous preparedness.
  • Identify federal and related organizations that impact hospital accreditation.
  • Differentiate organizations that create and promulgate standards, regulations, and best practices.
  • Analyze your organization’s compliance with medication-related CMS Conditions of Participation.
  • Rank the compliance of key conditions. 

Medication Use: Systems and Policy
ACPE: 0204-0000-24-765-H04-P&T
CE Hours: 3 contact hours
Activity Type: Application-based

  • Identify key elements in the design of safe medication systems.
  • Discuss strategies to promote a culture of safety through organizational planning.
  • Evaluate the influence of technology on the safety of medication use systems.
  • Summarize the role of an institution’s Pharmacy & Therapeutics committee in contributing to safe medication use.
  • Apply the principles of drug literature evaluation in the preparation of evidence-based literature reviews.
  • Differentiate between policies, procedures, and protocols.
  • Evaluate new and existing policies for compliance with regulatory standards.
  • Summarize the steps for development and implementation of policy, procedure, and protocol.
  • Develop a plan for organizational policy maintenance.
  • Summarize the role of pharmacy oversight committees as part of the overall corporate regulatory compliance program in an organization. 

Supply Chain Compliance
ACPE: 0204-0000-24-766-H04-P&T
CE Hours: 3 contact hours
Activity Type: Application-based

  • Assess select federal regulatory standards for pharmacy procurement, primarily those related to Drug Enforcement Administration requirements for controlled substances.
  • Summarize a brief history of the 340B program, its intended purpose, and basic program requirements for participating covered entities.
  • Compare 340B compliant inventory models.
  • Interpret key 340B program rules and regulations, primarily those related to group purchasing organization (GPO) prohibition, duplicate discounts, and program diversion.
  • Summarize the Drug Supply Chain and Security Act (DSCSA) and its intended purpose.
  • Identify basic requirements for health-system pharmacies to ensure compliance with new DSCSA regulations.
  • Explain the drug recall classification system as it relates to pharmacy considerations for a recall response.
  • Analyze the role regulatory bodies can play in common causes of drug shortages resolution.
  • Develop a mitigation strategy to address drug shortages at your institution.
  • Describe supply chain compliance oversight considerations for health systems. 

Risk Evaluation and Mitigations Strategy (REMS)
ACPE: 0204-0000-24-767-H04-P&T
CE Hours: 2.75 contact hours
Activity Type: Application-based

  • Describe how the FDA REMS program was established.
  • Differentiate the types of REMS requirements for patients, providers, and pharmacies / pharmacists.
  • Compare retail / community pharmacy and health system management of REMS medications.
  • Discuss REMS program infrastructure best practices.
  • Explain REMS documentation requirements.
  • Apply REMS requirements for audit preparation. 

Diversion Monitoring and Prevention
ACPE: 0204-0000-24-768-H04-P&T
CE Hours: 3.5 contact hours
Activity Type: Application-based

  • Define drug diversion.
  • Assess the impact drug diversion has on patients, the diverter, and the organization.
  • Interpret the DEA CFR as it relates to controlled substances processes.
  • Compare the diversion standards from The Joint Commission, Det Norske Veritas, and Centers for Medicare & Medicaid Services.
  • Differentiate the key individuals organizations should seek involvement from while building a diversion program.
  • Explain the role of the Diversion Response Team.
  • Summarize the investigations process.
  • Give examples related to internal and external reporting of diversion investigations.
  • Identify key internal and external partnerships that can assist in programming/advancement.
  • Give example(s) of innovative technology that may assist in diversion investigations.
  • Select the tools that may be used during a retail pharmacy diversion investigation. 

Compounding Compliance
ACPE: 0204-0000-24-769-H04-P&T
CE Hours: 4.5 contact hours
Activity Type: Application-based

  • Identify the standards of practice that apply to compounding.
  • Discuss provisions of the Pharmaceutical Quality, Security and Accountability Act.
  • Contrast federal mechanisms that influence sterile compounding practice.
  • Differentiate the roles of the Food and Drug Administration and states in sterile compounding regulation.
  • Identify other regulations related to workplace safety.
  • Describe the rationale of cleanroom design and airflow.
  • Discuss the importance of cleanroom behavior to protect compounded sterile preparations.
  • Analyze appropriate engineering controls for hazardous drug compounding.
  • Identify key elements of personal protective equipment required for hazardous drug compounding.
  • Apply standards for documentation to compounding records.
  • Define the scope of USP <825>.
  • List the personnel training requirements of USP <795>, USP <797>, and USP <800>.
  • Choose an appropriate remediation plan after evaluating personnel monitoring data results.
  • Explain the rationale of performing environmental monitoring in pharmacy cleanrooms.
  • Match microorganisms commonly found in pharmacy cleanrooms to their typical source(s). 

Quality Improvement, Assurance, Tools, and Software
ACPE: 0204-0000-24-770-H04-P&T
CE Hours: 2.75 contact hours
Activity Type: Application-based

  • Differentiate between quality improvement and quality assurance.
  • Discuss the significance of pharmacy in CMS Quality Assurance and Performance Improvement (QAPI) programs.
  • Plan QAPI principles into daily pharmacy practice.
  • Explain tools and strategies for comprehensive quality management.
  • Develop a continuous quality improvement plan for pharmacy processes using one of the QI tools.
  • Analyze compliance for pharmacy regulations and standards.
  • Assess scorecards as tools for performance assessment and tracking.
  • Create action plans based on scorecard analysis.

Amy Birch, PharmD
Manager, Therapeutic Policy
UF Health Jacksonville
Jacksonville, Florida 

Stacy L. Carson, PharmD, BCPS, FISMP
Program Director, Medication Safety
AdventHealth
Orlando, Florida 

Mallory Daniels, PharmD, MS, BCPS
Pharmacist Coordinator, Medication Use & Policy
UF Health Jacksonville
Jacksonville, Florida 

Michael Ganio, PharmD, MS, BCSCP, FASHP
Senior Director, Pharmacy Practice and Quality
ASHP
Bethesda, Maryland 

Jaclyn Jaskowiak, PharmD, BCPS, BCSCP
Inpatient Pharmacist Specialist
UC San Diego Health
La Jolla, California 

Patricia C. Kienle, RPh, MPA, BCSCP, FASHP
Director, Accreditation and Medication Safety
Cardinal Health
Wilkes-Barre, Pennsylvania 

Danielle Neal, PharmD, MBA, BCPS, CPEL, DPLA
Associate Vice President of Compliance- Pharmacy
Advocate Health
Charlotte, North Carolina

Abbi Rowe, PharmD, MHA, 340B ACE, BCSCP
Director, Pharmacy Supply Chain
AdventHealth Orlando, Central Fill Pharmacy
Orlando, Florida 

Rushabh Shah, PharmD, MBA, AAHIVP, CSP
System Director, Specialty and Home Delivery Pharmacy
UNC Health
UNC Shared Services Center Pharmacy
Durham, North Carolina

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

  • No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. 

As defined by the Standards of Integrity and Independence definition of ineligible company. 

Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

Important Note – ACPE 60 Day Deadline: 

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP profile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60-day deadline, ASHP will no longer be able to award credit for this activity.

The ASHP PROFESSIONAL CERTIFICATES℠ educational product line contains learning activities that are ACPE-accredited knowledge and application-based continuing education. This is not an ACPE Certificate Program. Upon successful completion of the activities, the learner will be able to download an ASHP Professional Certificate.